FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315754389> ?p ?o ?g. }

• W4315754389 endingPage "155" @default.
• W4315754389 startingPage "145" @default.
• W4315754389 abstract "Vericiguat is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event. To investigate the effects of vericiguat on QT interval in patients with chronic coronary syndromes (CCS). This was a randomized, phase Ib, placebo-controlled, double-blind, double-dummy, multicenter study. Vericiguat once daily was up-titrated from 2.5 mg to 5 mg and then to 10 mg (treatments A, B, and C) at 14-day intervals. Positive control was moxifloxacin 400 mg (single dose on day 8 or day 50; placebo on other days [treatment D]). We evaluated the placebo-adjusted change from baseline of the Frederica-corrected QTc interval (QTcF), pharmacokinetics, safety, and tolerability of vericiguat. In total, 74 patients with CCS, with mean (standard deviation) age 63.4 (8.0) years, were included and 72 patients completed the study. At each timepoint up to 7 h after administration, mean placebo-corrected change in QTcF from baseline was < 6 ms and the upper limit of the two-sided 90% confidence interval of the mean was below the 10-ms threshold for clinical relevance. Moxifloxacin confirmed the assay sensitivity. Median time of maximum concentration of vericiguat was 4.5 h post-dose. The adverse event profile of vericiguat was consistent with its mechanism of action, and the findings did not indicate any safety concerns. As part of an integrative risk assessment, this study demonstrated no clinically relevant corrected QT prolongation with vericiguat 10 mg once daily at steady state. ClinicalTrials.gov number, NCT03504982. Vericiguat is approved for treating worsening heart failure with reduced ejection fraction. As part of the safety evaluation of vericiguat, this study assessed its effect on the QT interval of the electrocardiogram. An electrocardiogram measures electrical activity of the heart. The QT interval is the time from the start of the Q wave to the end of the T wave. A longer than normal QT interval indicates an increased chance for abnormal heart rhythms. Usually, a QT study is conducted at high doses in healthy volunteers. Previous studies indicated that high doses of vericiguat may cause increased changes in blood pressure in healthy volunteers. Therefore, this study was performed in patients at a normal therapeutic dose. Patients with chronic coronary syndromes were enrolled rather than patients with heart failure with reduced ejection fraction, because they have fewer electrocardiogram abnormalities. The starting dose of vericiguat was 2.5 mg once daily, and the dose was increased to 5 mg and then to 10 mg at 14-day intervals. Placebo was tested for comparison and moxifloxacin (400 mg), a drug known to increase the QT interval, was tested to confirm that the study could detect a change in the QT interval. An increase in the QT interval of more than 10 ms was considered clinically relevant. Of 74 patients included, 72 completed the study. At each timepoint (up to 7 h after dosing), the difference between the QT change for vericiguat and placebo was less than 10 ms; therefore, vericiguat does not prolong the QT interval to a clinically relevant extent." @default.
• W4315754389 created "2023-01-13" @default.
• W4315754389 creator A5003046626 @default.
• W4315754389 creator A5014177046 @default.
• W4315754389 creator A5018328821 @default.
• W4315754389 creator A5018713537 @default.
• W4315754389 creator A5022923911 @default.
• W4315754389 creator A5025972354 @default.
• W4315754389 creator A5037371315 @default.
• W4315754389 creator A5041217307 @default.
• W4315754389 creator A5056136043 @default.
• W4315754389 creator A5068846586 @default.
• W4315754389 creator A5075947367 @default.
• W4315754389 creator A5083531787 @default.
• W4315754389 creator A5085710527 @default.
• W4315754389 creator A5090126429 @default.
• W4315754389 date "2023-01-12" @default.
• W4315754389 modified "2023-10-18" @default.
• W4315754389 title "Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes" @default.
• W4315754389 cites W1512187315 @default.
• W4315754389 cites W2011967639 @default.
• W4315754389 cites W2014020546 @default.
• W4315754389 cites W2095627701 @default.
• W4315754389 cites W2125570605 @default.
• W4315754389 cites W2338387536 @default.
• W4315754389 cites W3011371150 @default.
• W4315754389 cites W3013207865 @default.
• W4315754389 cites W3092720153 @default.
• W4315754389 cites W3096425772 @default.
• W4315754389 cites W3193598686 @default.
• W4315754389 cites W3207041866 @default.
• W4315754389 cites W3207828345 @default.
• W4315754389 doi "https://doi.org/10.1007/s40256-022-00557-2" @default.
• W4315754389 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36633816" @default.
• W4315754389 hasPublicationYear "2023" @default.
• W4315754389 type Work @default.
• W4315754389 citedByCount "3" @default.
• W4315754389 countsByYear W43157543892023 @default.
• W4315754389 crossrefType "journal-article" @default.
• W4315754389 hasAuthorship W4315754389A5003046626 @default.
• W4315754389 hasAuthorship W4315754389A5014177046 @default.
• W4315754389 hasAuthorship W4315754389A5018328821 @default.
• W4315754389 hasAuthorship W4315754389A5018713537 @default.
• W4315754389 hasAuthorship W4315754389A5022923911 @default.
• W4315754389 hasAuthorship W4315754389A5025972354 @default.
• W4315754389 hasAuthorship W4315754389A5037371315 @default.
• W4315754389 hasAuthorship W4315754389A5041217307 @default.
• W4315754389 hasAuthorship W4315754389A5056136043 @default.
• W4315754389 hasAuthorship W4315754389A5068846586 @default.
• W4315754389 hasAuthorship W4315754389A5075947367 @default.
• W4315754389 hasAuthorship W4315754389A5083531787 @default.
• W4315754389 hasAuthorship W4315754389A5085710527 @default.
• W4315754389 hasAuthorship W4315754389A5090126429 @default.
• W4315754389 hasBestOaLocation W43157543891 @default.
• W4315754389 hasConcept C118441451 @default.
• W4315754389 hasConcept C126322002 @default.
• W4315754389 hasConcept C142724271 @default.
• W4315754389 hasConcept C164705383 @default.
• W4315754389 hasConcept C197934379 @default.
• W4315754389 hasConcept C204787440 @default.
• W4315754389 hasConcept C27081682 @default.
• W4315754389 hasConcept C2778198053 @default.
• W4315754389 hasConcept C2778375690 @default.
• W4315754389 hasConcept C2778836808 @default.
• W4315754389 hasConcept C2780367336 @default.
• W4315754389 hasConcept C42219234 @default.
• W4315754389 hasConcept C44249647 @default.
• W4315754389 hasConcept C501593827 @default.
• W4315754389 hasConcept C71924100 @default.
• W4315754389 hasConcept C78085059 @default.
• W4315754389 hasConcept C86803240 @default.
• W4315754389 hasConcept C89423630 @default.
• W4315754389 hasConceptScore W4315754389C118441451 @default.
• W4315754389 hasConceptScore W4315754389C126322002 @default.
• W4315754389 hasConceptScore W4315754389C142724271 @default.
• W4315754389 hasConceptScore W4315754389C164705383 @default.
• W4315754389 hasConceptScore W4315754389C197934379 @default.
• W4315754389 hasConceptScore W4315754389C204787440 @default.
• W4315754389 hasConceptScore W4315754389C27081682 @default.
• W4315754389 hasConceptScore W4315754389C2778198053 @default.
• W4315754389 hasConceptScore W4315754389C2778375690 @default.
• W4315754389 hasConceptScore W4315754389C2778836808 @default.
• W4315754389 hasConceptScore W4315754389C2780367336 @default.
• W4315754389 hasConceptScore W4315754389C42219234 @default.
• W4315754389 hasConceptScore W4315754389C44249647 @default.
• W4315754389 hasConceptScore W4315754389C501593827 @default.
• W4315754389 hasConceptScore W4315754389C71924100 @default.
• W4315754389 hasConceptScore W4315754389C78085059 @default.
• W4315754389 hasConceptScore W4315754389C86803240 @default.
• W4315754389 hasConceptScore W4315754389C89423630 @default.
• W4315754389 hasIssue "2" @default.
• W4315754389 hasLocation W43157543891 @default.
• W4315754389 hasLocation W43157543892 @default.
• W4315754389 hasLocation W43157543893 @default.
• W4315754389 hasOpenAccess W4315754389 @default.
• W4315754389 hasPrimaryLocation W43157543891 @default.
• W4315754389 hasRelatedWork W1510771325 @default.
• W4315754389 hasRelatedWork W1984220118 @default.

• next